Macroautophagy is one of the major routes for the degradation of intracytoplasmic contents, including proteins and organelles such as mitochondria. The earliest morphologically recognizable intermediates in this pathway are phagophores, which evolve into double-membraned, sac-shaped structures. After the edges of the phagophores extend and fuse, engulfing a portion of cytoplasm, they become known as autophagosomes. These are then trafficked along microtubules in a direction that is biased toward the perinuclear microtubule-organizing center, where the lysosomes are clustered. This brings the autophagosomes close to lysosomes, enabling fusion of these different organelles, after which the lysosomal hydrolases degrade the autophagic contents ([Fig. 1](#fig1){ref-type="fig"}).

![**Schematic of autophagy.** Activation of AMPK and/or inhibition of mTORC1 by various stress signals induces activation of the ATG1--ULK1 complex, which positively regulates the activity of the VPS34 complex via phosphorylation-dependent mechanisms. Class III PI3K VPS34 provides PI3P to the phagophore, which seems to define the LC3-lipidation sites by assisting in the recruitment of the ATG12--ATG5--ATG16L1 complex to the membrane (asterisks). After the binding of ATG12--ATG5--ATG16L1 complex to the phagophore and LC3 conjugation to PE (LC3-II), the membrane elongates and engulfs portions of the cytoplasm, ultimately leading to the formation of the complete autophagosome. Proteins such as p62, NDP52, and NBR1 confer substrate selectivity to the pathway by establishing a bridge between LC3-II and specific ubiquitinated cargo (e.g., aggregates, microbes, mitochondria, and peroxisomes), through their LIR and UBA domains, respectively. In the final step of the process, autophagosomes fuse with lysosomes, resulting in the degradation of the vesicle contents. AMPK, AMP-activated protein kinase; mTORC1, mechanistic target of rapamycin complex 1; ULK, Unc-51-like kinase; VPS34, phosphatidylinositol 3-kinase VPS34; PI3P, phosphatidylinositol 3-phosphate; PE, phosphatidylethanolamine; LIR, LC3-interacting region; UBA, ubiquitin associated domain.](JEM_20150956_Fig1){#fig1}

There are two additional forms of autophagy that will not be considered in detail in this review. Microautophagy involves the direct sequestration of portions of the cytoplasm by lysosomes, and has been mainly studied in yeast. Chaperone-mediated autophagy captures proteins that contain a pentapeptide motif related to KFERQ via Hsc70, which targets proteins to LAMP2A. LAMP2A then serves as a translocation channel to enable import of such substrates into the lysosomes. This pathway is perturbed by proteins causing certain neurodegenerative diseases and has been reviewed in detail elsewhere ([@bib19]).

Much of the pioneering work in the macroautophagy (henceforth referred to as autophagy in this review) field was initiated in yeast, where autophagy protects against cellular starvation. Although this role is conserved across evolution, more recent studies in mammalian systems have highlighted the importance of autophagy in diverse areas of physiology and disease. In this review, we will focus on the protective roles of autophagy in neurodegenerative and infectious diseases ([Fig. 2](#fig2){ref-type="fig"}). We will start by outlining the basic models where autophagosomes engulf and degrade neurodegeneration-associated aggregate-prone proteins or infectious agents. We will then describe possible mechanisms for enhancing the capture of such substrates to extents greater than would occur with bulk autophagy, during which one assumes there is random sequestration of cytoplasmic contents. We will extend the discussion of the roles of autophagy in these diseases by considering more complex consequences, including control of cell death, immunity, and inflammation. Although there are aspects that have been explored more in neurodegenerative diseases than infectious diseases, and vice versa, we believe that the opportunity to consider both in parallel will enable consideration of new hypotheses and cross-fertilization. We propose that the two main areas of overlap between the roles of autophagy in neurodegeneration and infectious disease are: (a) similarities in the shared usage of autophagic receptors in defending against pathology-inducing agents in both classes of disease ([@bib4]), and (b) the now well-documented antiinflammatory action of autophagy ([@bib21], [@bib22]). This juxtaposition of autophagic roles in apparently distinct classes of diseases is a testament to the relevance of autophagy in cleansing the cellular interiors no matter what the disease context is, and is particularly timely in view of the explosion of data in the two fields. Finally, we will consider possible autophagy-related therapeutic strategies that may be of significance for these diseases, including the possibility of developing agents that may target both sets of conditions.

![**Protective roles of autophagy in neurodegenerative and infectious diseases.** A major role for autophagy in neurodegenerative and infectious diseases involves the clearance of toxic aggregate-prone proteins and infectious agents, respectively. However, it also exerts ancillary beneficial roles by controlling cell death and exacerbated inflammatory responses associated with these pathologies.](JEM_20150956R_Fig2){#fig2}

Autophagy biology
=================

The membranes that contribute to phagophore formation and elongation may derive from multiple sources, including the ER (including ER exit sites and ER--mitochondrial contact sites; [@bib46]; [@bib43]), the ER--Golgi intermediate compartment ([@bib39], [@bib40]), recycling endosomes ([@bib67]; [@bib104]), plasma membrane ([@bib109]; [@bib82]), the Golgi complex ([@bib148]; [@bib92]), and, potentially, lipid droplets ([@bib27]; [@bib127]). The coordination of the membrane rearrangements that enable autophagosome formation, and their subsequent delivery to the lysosomes, is regulated by multiple autophagy-related (ATG) proteins. Some of these participate in two ubiquitin-like conjugation reactions. The first involves ATG12 conjugation to ATG5. This ATG12--ATG5 conjugate binds noncovalently with ATG16L1 to form a complex essential for phagophore expansion ([@bib112]). These complexes are localized to the phagophore and dissociate after the autophagosome is formed. The completion of autophagosome formation is assisted by a second conjugation reaction involving ATG8/LC3. LC3 is first cleaved by ATG4 to form cytosolic LC3-I, which is conjugated to phosphatidylethanolamine on autophagosome precursors to form membrane-associated LC3-II.

Autophagy signaling
===================

A primordial signaling pathway regulating autophagy, which is conserved from yeast to humans, is mediated by the mammalian target of rapamycin complex 1 (mTORC1), which inhibits autophagy by phosphorylating proteins such as ATG1 and ATG13 that act upstream in phagophore formation ([@bib48]; [@bib55]). However, several mTORC1-independent pathways have been described, including low inositol triphosphate levels ([@bib119]), which activate autophagy by activating AMP-activated protein kinase (AMPK). Low inositol triphosphate levels reduce calcium flow from the ER to mitochondria, and the lower intramitochondrial calcium levels inhibit oxidative phosphorylation, thereby decreasing ATP levels, which activates AMPK ([@bib11]). Some signals activate autophagy by stimulating III phosphatidylinositol 3-kinase (called VPS34), which produces phosphatidylinositol 3-phosphate (PI3P); this, in turn, helps to recruit ATG16L1 to sites of autophagosome formation ([@bib24]). Some of these signals act via the ATG6 orthologue Beclin 1, which stimulates VPS34 activity ([@bib38]; [@bib115]). However, PI3P-independent forms of autophagy have also been described, and some of these appear to be mediated via the use of PI5P as an alternative to PI3P ([@bib139]). Interestingly, many of the stimuli that induce autophagy are stress responses. For example, mTORC1 activity is inhibited by amino acid starvation ([@bib14]), the levels of PI5P are induced by glucose starvation ([@bib139]), and AMPK (a key sensor of ATP levels in the cells) is enhanced when ATP energy stores are reduced ([@bib44]). These pathways are also directly linked to antiinfective or general immune signaling players, such as IRGM (an antituberculosis and Crohn's disease factor that interacts with ULK1 and Beclin 1, promoting their coassembly; [@bib13]), TAK1 and NOD2/RIPK2 (which activate AMPK and ULK1, respectively), and NLRP (which interacts with Beclin 1). The pathways also receive input from TLRs, IL-1β, and other immune system regulators ([@bib21]).

In the context of neurodegenerative diseases such as Huntington's disease (HD), there appears to be a decrease in mTORC1 activity in neurons with large aggregates ([@bib108]). However, the ultimate consequences for autophagy may not be straightforward, as excitotoxicity will increase calcium levels, which in turn inhibits autophagosome biogenesis ([@bib146]), whereas mutant huntingtin binds the autophagy inducer Rhes to impair autophagy ([@bib76]). Thus, the eventual consequences of a specific mutation or disease situation are frequently unpredictable, as multiple activating and inhibitory pathways may be affected. Furthermore, non--cell-autonomous effects may have an impact. For example, the increased nitric oxide released by glial cells in diseases such as Alzheimer's disease impairs autophagosome biogenesis ([@bib121]).

How autophagy clears aggregate-prone intracytoplasmic proteins
==============================================================

Intracellular protein misfolding and aggregation are features of many late-onset neurodegenerative diseases, which are referred to as proteinopathies. These include Alzheimer's disease, Parkinson's disease, tauopathies, and polyglutamine expansion diseases (including HD and various spinocerebellar ataxias \[SCAs\]). Currently, there are no effective therapeutic strategies that slow or prevent the neurodegeneration resulting from these diseases in humans. The mutations that cause HD and many other proteinopathies (e.g., polyglutamine diseases and tauopathies) confer novel toxic functions on the specific protein, and disease severity frequently correlates with expression levels. Thus, it is important to understand the factors regulating the expression levels of these aggregate-prone proteins. When these proteins are intracytoplasmic, they can be removed either via the ubiquitin-proteasome system or via autophagy. Whereas the former route is generally more rapid, it is restricted to species that can enter the narrow proteasome barrel, which precludes oligomers and higher order structures. These species can be cleared by autophagy. Consistent with the model above, the aggregate-prone forms of such proteins, including tau ([@bib2]), α-synuclein ([@bib143]; [@bib128]), mutant huntingtin ([@bib106]), and mutant ataxin 3 ([@bib2]) appear to have a higher dependency on autophagy for their clearance compared with the wild-type forms.

Autophagy in infectious and inflammatory diseases
=================================================

In the context of infectious and inflammatory diseases, autophagy plays at least three roles. Autophagy can clear intracellular microbes and moderate host innate immune responses to microbial products (through recognition of pathogen-associated molecular patterns \[PAMPs\]) and endogenous sources of inflammation (via recognition of damage-associated molecular patterns \[DAMPs\]; [@bib21]). In addition, autophagy may also protect by enhancing the removal of relevant toxins, such as *Staphylococcus aureus* α-toxin ([@bib75]).

The direct elimination of microbes by autophagy (a process termed xenophagy) receives the most attention, although it is likely that the antiinflammatory role of autophagy independent of, or during, infection plays an equally important host protective role ([@bib22]). The former perception is understandable, as intracellular microbes such as invading bacteria or viruses are large intracytoplasmic objects that represent potential (and in many cases actual) substrates for autophagic removal. Prototypical examples of this are *Mycobacterium tuberculosis* in infected macrophages ([@bib42]) and animal models ([@bib12]; [@bib142]; [@bib72]) and the Group A *Streptococcus* that manages to invade host cells ([@bib85]), but many other bacteria (including *Listeria*, *Salmonella*, and *Shigella*) are at least partially susceptible to autophagic elimination when tested in cellular systems ([@bib41]; [@bib50]). Similarly, viruses, including HIV ([@bib60]; [@bib126]; [@bib71]; [@bib10]; [@bib116]), as well as protozoans ([@bib15]), can be targeted by conventional or modified forms of autophagy. In many cases, an evolutionary balance exists whereby the host's ability to deploy autophagy against the microbe is countered by bacterial or viral adaptations, and in most instances a successful intracellular pathogen has very specific antiautophagy strategies ([@bib50]). Such adaptations are seen in a wide range of pathogens, including *Shigella* and *Legionella* ([@bib50]), *Mycobacterium tuberculosis* ([@bib22]), HSV-1 ([@bib94]; [@bib70]), and HIV ([@bib60]; [@bib7]). Interestingly, interactions between autophagy and viral products can lead to neurological manifestations; for example, HIV proteins have been associated with HIV-induced dementia and manifestations of neuroAIDS ([@bib80]; [@bib29]; [@bib33]). As with other host--pathogen interactions, a balance between a microbe and the host is established, leading to chronic disease or subclinical or latent infection, as in latent tuberculosis or persistent viral infections. This represents a therapeutic opportunity to tip the balance against the pathogen by enhancing autophagy using pharmacological intervention. However, in several cases, evidence of microbial exploitation of autophagy (not just defense against it, but in some cases enhancing survival or promoting spread) suggests that this approach must be carefully tailored. Some examples of the latter include *Brucella* ([@bib131]), *Anaplasma* (formerly *Ehrlichia*; [@bib88]), and poliovirus ([@bib3]).

Autophagy receptor proteins
===========================

Whereas autophagy was originally considered to be a nonselective bulk degradation process, accumulating data now supports the concept of selective macroautophagy, where the cell uses receptor proteins to enhance the incorporation of specific cargoes into autophagosomes. These receptor proteins include p62 ([@bib6]; [@bib96]), optineurin ([@bib145]), NDP52 ([@bib136]), NBR1 ([@bib57]), ALFY ([@bib34]), TRIM5 ([@bib71]), and Tollip ([@bib68]). The canonical model for this process involves these receptors binding to cargoes, typically via interaction with ubiquitinated motifs, and the receptor binding to the autophagosome membrane protein LC3 via LC3-interacting domains ([@bib4]; [@bib133]). However, some classical receptors, like p62 and NBR1, may not require LC3-binding to be incorporated into autophagosomes ([@bib52]). Although systematic studies have not yet been performed, many of these receptors, including p62 and optineurin, appear to be able to assist autophagic capture of both neurodegenerative disease-causing proteins and infectious agents. In their antimicrobial role, these receptors are referred to as a new class of pattern recognition receptors termed sequestosome 1/p62-like receptors ([@bib4]; [@bib21], [@bib22]). The ability of receptor proteins to recruit substrates to autophagosomes can also be modulated by posttranslational modifications. For example, the TANK-binding kinase 1 (TBK1) phosphorylates optineurin on Ser177, enhancing LC3-binding affinity and autophagic clearance of substrates, such as expanded polyglutamines as seen with mutant huntingtin ([@bib59]), and *Salmonella* ([@bib145]). Likewise, TBK1- ([@bib100]) or casein kinase-mediated ([@bib74]) phosphorylation of p62 at residue S403 has additional benefits in enhancing recognition of ubiquitinated targets by the ubiquitin-associated (UBA) domain of p62, as is observed in clearance of polyglutamine expansion targets ([@bib74]) or mycobacteria ([@bib100]). Enhancement of ubiquitin recognition by the p62 UBA is also under control of direct phosphorylation by ULK1, which phosphorylates Ser405 and Ser409 of murine p62 (equivalent to human Ser403 and Ser407; [@bib66]). ULK1-mediated phosphorylation of the former residue additionally destabilizes the UBA dimer interface, thus increasing binding affinity of p62 to ubiquitin in response to proteotoxic stress ([@bib66]). In the case of p62, and possibly other molecules, the activity of receptors can themselves be influenced by a disease protein. Huntingtin, the Huntington disease-causing protein, appears to act as a scaffold for selective macroautophagy but it is dispensable for bulk autophagy ([@bib89]; [@bib114]). Huntingtin interacts with p62 to enhance its interactions with LC3 and with ubiquitin-modified substrates ([@bib114]). Interestingly, in some cases, such as with optineurin ([@bib138]) and TRIM5α ([@bib71]), the adaptor proteins themselves also can act as bulk autophagy regulators. It is interesting to note that several of these proteins, including p62, TBK1, and optineurin, are mutated in neurodegenerative diseases such as motor neuron disease and forms of frontotemporal dementia ([@bib73]; [@bib32]; [@bib36]; [@bib102]). Of further note is the shared role of autophagy receptors in protection against neurodegeneration and infectious agents, a principle that may extend to new receptor categories (e.g., TRIMs or other classes), as their functions are further elucidated with future progress in selective autophagy.

Additional protective properties of autophagy in neurodegenerative and infectious diseases
==========================================================================================

A major consequence of autophagy in many of these diseases is promotion of the removal of toxic proteins or infectious agents, but there may be additional benefits. Autophagy is generally an antiapoptotic process that reduces caspase activation ([@bib107]; [@bib49]; [@bib1]; [@bib81]). In a manner similar to what has been observed in yeast, autophagy inhibition sensitizes mammalian cells to nutrient deprivation, whereas autophagy compromise results in apoptosis ([@bib8]). Consistent with this, autophagy activation protects against proapoptotic insults in culture and in vivo. This may be relevant in neurodegenerative diseases, where subapoptotic caspase activities may enhance disease by processes including cleavage of proteins like mutant huntingtin ([@bib144]; [@bib141]) or tau ([@bib111]) to increase their toxicities, or by trimming of dendritic spines ([@bib103]; [@bib31]).

Autophagy also regulates inflammation. As recently reviewed ([@bib22]), the antiinflammatory functions of autophagy in principle involve: (a) prevention of spurious inflammasome activation and down-regulation of the response once inflammasome is activated ([@bib117]; [@bib86]; [@bib152]; [@bib69]) and (b) inhibition of type I IFN responses directly ([@bib54]; [@bib118]; [@bib58]; [@bib65]) or indirectly ([@bib135]; [@bib65]). The underlying processes include autophagic elimination of endogenous DAMPs (e.g., depolarized mitochondria leaking ROS, mitochondrial DNA, and oxidized mitochondrial DNA; [@bib117]; [@bib86]; [@bib152]; [@bib69]), which lowers the threshold for inflammasome activation, or direct targeting and degradation of inflammasome components and products such as NLRP3, ASC, and IL-1β ([@bib45]; [@bib125]; [@bib17]); this, in turn, tapers the intensity and duration of inflammasome activation. However, the engagement of autophagy with cellular outputs of IL-1β, a prototypical unconventionally secreted protein, is more complex ([@bib26]; [@bib101]). Autophagy assists secretion of IL-1β ([@bib26]; [@bib93]; [@bib140]), a cytosolic protein that lacks a signal peptide and is unable to enter the conventional secretory pathway via the ER and Golgi. Thus, autophagy also plays a positive role in delivering IL-1β and possibly other proinflammatory substrates, once they are properly activated in the cytosol, to the extracellular space where they perform their signaling functions ([@bib101]).

The autophagic interference with type I IFN responses occurs either directly by targeting signaling molecules within the pathway, starting with RIG-I-like receptors or cGAMP synthase (sensors recognizing cytosolic nucleic acids) and converging upon stimulator of the interferon gene (STING) and interferon regulatory factors ([@bib54]; [@bib118]; [@bib58]; [@bib65]), or indirectly by removing agonist sources that activate these pathways ([@bib135]; [@bib65]). The p62 receptor also appears to have a role in restraining TCR activation of NF-κB signaling mediated by Bcl10. Although p62 enables the signaling to occur in the first place, it also serves as a receptor to degrade Bcl10, which becomes ubiquitinated as a response to TCR activation. Thus, this mechanism may serve to protect cells from NF-κB hyperactivation in response to TCR signaling ([@bib98]). The antiinflammatory action of autophagy applies to both infectious and inflammatory diseases (either sterile or associated with microbial triggers), such as Crohn's disease. These relationships may extend to neuroinflammation in acute and chronic neurological disorders. Many neurodegenerative diseases are associated with inflammatory responses in glia, which may contribute to pathology ([@bib20]), and it is possible that autophagy in glial cells may play a role in keeping these processes in check, although this domain has not been carefully explored.

Autophagy also plays key roles in protecting cells against infectious agents that either remain within vacuoles or escape from phagosomes into the cytoplasm ([@bib50]). Examples of intracellular bacterial pathogens in most cases represent a mixed spectrum of retention within the parasitophorous vacuole, partial permeabilization of such vacuoles, or full escape of bacteria into the cytosol. Such mixed events are often skewed to one or the other end of the spectrum, with *Shigella* ([@bib90]; [@bib25]; [@bib84]; [@bib91]; [@bib137]) and *Listeria* ([@bib105]; [@bib84]) predominantly escaping into the cytosol, whereas *Salmonella* ([@bib151]; [@bib145]; [@bib51]; [@bib137]; [@bib41]) and *M. tuberculosis* ([@bib42]; [@bib142]; [@bib72]; [@bib22]) primarily reside in undamaged vacuoles although recent studies indicate that it penetrates into the cytosol. Parallels may exist in neurodegenerative diseases, where autophagy may help glial cell clearance of extracellular β-amyloid if the internalized peptide is found to gain access to the cytosol ([@bib64]). This principle may be also relevant to diseases like Parkinson's disease and forms of frontotemporal dementia, where there is increasing evidence for extracellular spread of the relevant toxic proteins like α-synuclein and tau via prion-like mechanisms ([@bib23]; [@bib37]; [@bib62]; [@bib132]). However, impaired clearance of autophagosomes due to defective lysosomal function may cause excess secretion of such proteins and exacerbate extracellular spread ([@bib28]; [@bib63]).

Therapeutic and clinical implications
=====================================

Up-regulation of autophagy via mTORC1-dependent and -independent routes has been shown to enhance the clearance of neurodegenerative disease-causing proteins and reduce their toxicity in a wide range of cells in *Drosophila*, zebrafish, and mouse models ([@bib108]; [@bib38]; [@bib120]; [@bib150]; [@bib99]; [@bib77]; [@bib129]; [@bib18]; [@bib123]; [@bib47]; [@bib35]). This strategy has shown promise in a range of disease models, including tauopathies, α-synucleinopathies, HD, spinocerebellar ataxia type 3, and familial prion disease. The drugs used in these diseases include a rapamycin analogue and mTOR-independent autophagy inducers like rilmenidine and trehalose ([@bib35]; this work also considers the points of action of many of these drugs). Conversely, autophagy inhibition enhances the toxicity of these proteins and, in parallel, leads to the accumulation of the relevant protein ([@bib35]).

Similarly, autophagy up-regulation may enhance the clearance of a range of infectious agents, with some of the more developed aspects being shown with *M. tuberculosis*, including multidrug-resistant (MDR) strains. In some cases, the support for this type of strategy has been strengthened by mouse models and preclinical data. For example, drugs used for psychiatric and neurological disorders such as the antidepressants fluoxetine ([@bib130]) and nortriptyline ([@bib134]), and the antiepileptic carbamazepine ([@bib113]; [@bib124]), have been shown to counter *M. tuberculosis* infection, possibly through autophagy. Notably, carbamazepine, an inducer of autophagy, has been shown to act on MDR *M. tuberculosis* in vivo ([@bib124]). Furthermore, several tyrosine kinase inhibitors, which also act as inducers of autophagy, have been tested in vitro and in mouse models for their potential in host-directed therapy (HDT) in tuberculosis. This includes gefitinib, an inhibitor of the tyrosine kinase epidermal growth factor receptor (EGFR) shown to activate autophagy and suppress *M. tuberculosis* in macrophages and, to some extent, in infected mice ([@bib130]). It also includes imatinib (Gleevec), a known inducer of autophagy ([@bib30]) and inhibitor of the tyrosine kinase Abl, whose depletion has been shown to suppress intracellular *M. tuberculosis* ([@bib53]), with imatinib reducing *M. tuberculosis* bacillary loads in infected macrophages ([@bib9]) and in a mouse model of tuberculosis ([@bib87]). Other antituberculosis HDT autophagy-inducing candidate drugs include antiparasitic pharmaceuticals such as nitozoxanide ([@bib61]) and cholesterol-lowering drugs, i.e., statins ([@bib97]).

There may be a wide range of strategies that could be used in human conditions, including drugs (where several FDA-approved drugs show promise in preclinical models), peptides ([@bib126]), and possibly topical agents for certain infectious agents. Furthermore, there may be opportunities for modulating selective autophagy via adaptor proteins. Strategies could include regulating posttranslational modifications of proteins that could enhance their activities.

Neurodegenerative disease-causing proteins and various infectious agents can also impair autophagy. Although this issue has been dealt with in detail elsewhere ([@bib78]), one recent example includes the VPS35 D620N Parkinson's disease mutation that impacts early stages of autophagosome biogenesis ([@bib149]). PICALM, an Alzheimer's disease GWAS hit, impacts both autophagosome formation and autophagosome degradation, and altered PICALM activity in culture and in vivo leads to the accumulation and increased toxicity of tau, a protein which is an important driver of Alzheimer's disease pathogenesis ([@bib83]). Likewise, infectious agents like *Salmonella* ([@bib79]; [@bib95]), *Legionella* ([@bib16]), *Shigella* ([@bib90]), *Listeria* ([@bib5]; [@bib147]), and viruses ([@bib94]; [@bib60]; [@bib70]; [@bib7]) have multiple mechanisms that can at least partially counter or fully impair autophagy. In extreme cases, some infectious agents can convert autophagosomes into a replicative ([@bib88]) or persistence ([@bib5]) niche.

Understanding the biology of the relevant disease and the proposed treatment modality will enhance the probability of successful therapies. In diseases where there is impaired autophagosome degradation, including the lysosomal storage diseases, there may be concerns about the risks versus the benefits of increasing autophagosome biogenesis. However, this may depend on the extent of the block of autophagosome degradation, as stimulation of autophagosome biogenesis appeared to enhance autophagic substrate clearance in cell culture models of Niemann-Pick Type C1 ([@bib122]), a lysosomal storage disease associated with delayed autophagosome degradation.

Likewise, it is important to understand the actions and possible side effects of drugs used for these diseases. For example, azithromycin, a potent antibiotic, is used as a prophylactic against mycobacterial infections in cystic fibrosis patients. However, mycobacteria that develop resistance against azithromycin accumulate in culture and in vivo when treated with this agent, as azithromycin also impairs autophagosome degradation ([@bib110]). Thus, the advantages of this drug as an antimicrobial for sensitive species may be, in part, counterbalanced by the risks of autophagy inhibition for resistant mycobacterial species. This possibility is suggested by preliminary clinical data which have reported increased risks of resistant nontuberculous mycobacterial infections in cystic fibrosis patients treated chronically with azithromycin.

Future directions
=================

Extensive preclinical animal model data support the promise of the therapeutic use of autophagy up-regulation in various neurodegenerative and infectious diseases. This aim may be achievable with existing approved drugs using repurposing strategies. Here, a major challenge will be making the transition between mice and humans, where one needs to contend with very different pharmacokinetics for drugs between the species. However, in these scenarios, the task is simplified by the existing human safety and pharmacokinetics data on the drugs. It is likely that most, if not all, of the approved drugs that influence autophagy have effects on other pathways, and although these may not be limiting or even disadvantageous, there would be major advantages both for experimental studies and possibly human treatments to identify more specific autophagy modulators. These may be more elusive than previously anticipated, given the increasing awareness of autophagy-independent roles of many ATG proteins.

A second major hurdle with such drug discovery efforts is disease modeling. It is currently impossible to model sporadic Alzheimer's and Parkinson's disease in rodents. These limitations may be partially mitigated if suitable iPS stem cell--derived neuronal models are generated for sporadic cases. These difficulties may be less of an issue for monogenic diseases that can be more faithfully recapitulated in mice. However, even in these cases, the disease course is often much more rapid in the models, which may have consequences for the way one interprets the preclinical data.

Future work will establish the potential for harnessing autophagy as a therapeutic option in various neurodegenerative and infectious diseases.
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**Note added in proof.** While this manuscript was in production, further evidence of the extensive overlaps between inflammatory response systems and autophagy was documented in the context of cyclic GMP-AMP synthase (cGAS)-dependent type I IFN production and autophagic clearance of *M. tuberculosis*. (Collins, A.C., H. Cai, T. Li, L.H. Franco, X.D. Li, V.R. Nair, C.R. Scharn, C.E. Stamm, B. Levine, Z.J. Chen, and M.U. Shiloh. 2015. *Cell host Microbe*. 17:820-828; Watson, R.O., S.L. Bell, D.A. MacDuff, J.M. Kimmey, E.J. Diner, J. Olivas, R.E. Vance, C.L. Stallings, H.W. Virgin, and J.S. Cox. 2015. *Cell host Microbe*. 17:811-819).

Abbreviations used:AMPKAMP-activated protein kinaseATGautophagy-relatedDAMPdamage-associated molecular patternHDHuntington's diseasemTORC1mammalian target of rapamycin complex 1PAMPpathogen-associated molecular patternSCAspinocerebellar ataxiaTBK1TANK-binding kinase 1UBAubiquitin-associated
